Nabi Biopharma to Receive $5M from GSK

MSN Money reports that Nabi Biopharma is to receive a $5 million milestone payment from GlaxoSmithKline Biologicals Co as Nabi Biopharma announces the initiation of a Phase I/II clinical trial for two of the antigens in the PentaStaph vaccine candidate, which is now owned by GlaxoSmithKline Biologicals (GSK). As a result of the initiation of the trial, Nabi is eligible for and has invoiced GSK $5 million for successful completion of this milestone due under the agreement governing Nabi's sale of PentaStaph and related assets to GSK. This milestone payment was contingent on initiation of the Phase I clinical trial for two PentaStaph antigens that target the most virulent toxins produced by the bacteria.

Learn more: Market Report -- In Play (NABI)

Share this article with your social network, just click below to share now!

Share |

Pfizer Plans to Disclose Payments Made to Clinical Investigators

According to Clinical Trials Today, Pfizer plans to publicly report payments made to clinical investigators, physicians and other health care professionals by early next year, making it the first pharmaceutical company to commit to disclosing payments it makes for conducting clinical trials, speaking and consulting. It seems that Pfizer wants to aim for transparency of their practices, perhaps providing an easier system of due diligence within the pharmaceutical and CRO/Clinical Trials arenas. What do you think of this move by Pfizer?

Share this article with your social network, just click below to share now!

Share |